论文部分内容阅读
丙型肝炎(非甲非乙型肝炎)约占输血后所发生的肝炎病例的90%。尽管近年供血的质量已有所改善,但据估计在接受输血的人群中发生急性肝炎者仍有5～10%。在这些急性丙型肝炎病人中,至少有一半发展成为慢性肝炎,而后者又至少有20%发展成为肝硬化。目前尚无治疗慢性丙型肝炎有效的临床对照试验有关报告,只有几个初步报告提出α干扰素和β干扰素对治疗这些病人有好处。为此,作者进行了一项随机对照试验,以评价重组α干扰素对慢性丙型肝炎的疗效。
Hepatitis C (non-A, non-B) accounts for about 90% of the hepatitis cases that occur after transfusion. Although the quality of blood supply has improved in recent years, it is estimated that there are still 5% to 10% of those who develop acute hepatitis in transfusion recipients. At least half of these patients with acute hepatitis C develop chronic hepatitis, while at least 20% of those patients develop cirrhosis. There are currently no available controlled clinical trials for treating chronic hepatitis C and only a few preliminary reports suggest that interferon-alpha and interferon-beta are good for the treatment of these patients. To this end, the authors conducted a randomized controlled trial to evaluate the efficacy of recombinant interferon alpha in chronic hepatitis C treatment.